SCHEMBL6499248

SCHEMBL6499248

CC1(CN2CCC(c3ccccc3)CC2)CCc2cc(-c3ccccc3)ccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.48
HRH3 Q9Y5N1 1/20 0.40
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39
HTR7 P34969 2/20 0.39
DRD2 P14416 2/20 0.39
HTR1A P08908 1/20 0.38
ADRA1B P35368 1/20 0.38
CCR5 P51681 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
TDP2 O95551 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493159 0.86 SIGMAR1 (0.47) DGAT1DRD2CCR5SIGMAR1
SCHEMBL6503951 0.85 DRD2 (0.40) HRH3PARP10HTR7DRD2ADRA1B
SCHEMBL8191001 0.82 ADRA1D (0.51) HRH3DRD2ADRA1BSIGMAR1ALDH1A1
SCHEMBL8203575 0.76 DRD2 (0.45) DGAT1DRD2SIGMAR1ALDH1A1DRD4
SCHEMBL6489774 0.74 HTR7 (0.43) HTR7DRD2ADRA1BCCR5SIGMAR1
SCHEMBL6501747 0.74 SIGMAR1 (0.53) DGAT1HRH3DRD2HTR1ACCR5
SCHEMBL8199080 0.72 CYP26A1 (0.49) DGAT1HRH3HTR7DRD2SIGMAR1
Benzene SCHEMBL6503241 0.70 DRD2 (0.43) HTR7DRD2HTR1AADRA1BSIGMAR1
SCHEMBL7129359 0.70 APP (0.42) HTR7DRD2HTR1ACCR5SIGMAR1
SCHEMBL7127231 0.70 SIGMAR1 (0.46) DRD2SIGMAR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998036749-A1 TETRALONE DERIVATIVES AS ANTIARRHYTHMIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-08-27 WO claimed
US-6969724-B2 Compounds SMITHKLINE BEECHAM-SPA (GB) 2005-11-29 US disclosed
US-20040024218-A1 Novel compounds SMITHKLINE BEECHAM SPA 2004-02-05 US disclosed
EP-1129072-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS Smithkline Beecham S.p.A. (IT) 2001-09-05 EP disclosed
WO-2000027815-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS SMITHKLINE BEECHAM SPA (IT) 2000-05-18 WO disclosed
US-6048877-A Tetralone derivatives as antiarrhythmic agents BRISTOL-MYERS SQUIBB COMPANY (US) 2000-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024218-A1 Novel compounds OXER1, CLIC1, CCR1 DGAT1 1043/4885HRH3 276/4885PARP10 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.